Clinical Trials | October 27, 2022
Camizestrant significantly improved PFS vs. Faslodex in SERENA-2 Phase II trial
Results reinforce commitment to next-generation oral SERD development programme
Results reinforce commitment to next-generation oral SERD development programme
On the Capex front, the company has invested Rs. 416 crore in the first half and it is broadly in line with our guidance for the two years around Rs. 2,000 crore across all the subsidiaries and divisions
Separate Phase 3 study evaluating 200 days of therapy with PREVYMIS in HSCT recipients at high risk of late clinically significant CMV infection recently completed, meeting its primary endpoint
The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
Esiloc was launched at the biggest doctor engagement webinar involving more than 12,000 doctors across the country
CGHS would give robust coverage to pensioners and with new innovations and practices
NABH shall encourage and provide assistance in onboarding their accredited/certified facilities on ABDM’s Health Facility Registry
For the last ten financial years, the company has posted healthy performance with its revenue from operations growing at 15% CAGR and net profit at 23% CAGR
This first joint plan on One Health aims to create a framework to integrate systems and capacity so that we can collectively better prevent, predict, detect, and respond to health threats
Subscribe To Our Newsletter & Stay Updated
